(Q33865552)

29 July 2017

1 reference

title

Update on highly active antiretroviral therapy: progress and strategies (English)

1 reference

29 July 2017

anti-retroviral agent

0 references

author name string

Clumeck N

series ordinal

1

1 reference

PubMed ID

10721456

29 July 2017

De Wit S

series ordinal

2

1 reference

29 July 2017

1 February 2000

1 reference

Biomedicine and Pharmacotherapy

29 July 2017

1 reference

29 July 2017

54

1 reference

29 July 2017

1

1 reference

29 July 2017

7-12

1 reference

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

Choosing the best initial therapy for HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988634-5

7 January 2021

10.1016/S0753-3322(00)88634-5

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10721456